MOTS-C Peptide Dosage Chart: How Much to Take (And When It Actually Matters)

The Peptide Everyone's Injecting — But Nobody's Dosing Correctly

If you've spent any time in longevity circles lately, you've probably heard about MOTS-C. The biohacking crowd is injecting it before workouts. Metabolic health researchers are calling it one of the most interesting mitochondrial peptides discovered in the last decade. And somewhere in the middle of all that enthusiasm, the question of how much to actually take has gotten completely buried under vibes and bro-science.

Here's what you need to know upfront: MOTS-C is a mitochondria-derived peptide that your body actually makes naturally. It plays a genuine role in metabolic regulation, insulin sensitivity, and cellular energy balance. The research is early but real. And the dosing — unlike what half the forums will tell you — is not one-size-fits-all. It depends on your goal, your body, your cycle length, and yes, if you're a woman, your biology specifically.

This guide breaks down the MOTS-C dosage chart practically: what ranges appear in the literature, how protocols are structured by goal, when to inject, how to cycle it, and what to watch for. No hype. No invented numbers. Just what the evidence actually supports.

What Is MOTS-C, Really?

MOTS-C (Mitochondrial Open Reading Frame of the 12S rRNA type-C) was first identified in 2015 by researchers at USC — specifically by Pinchas Cohen's lab, which has become one of the leading groups in mitochondrial peptide research. Here's the thing that makes it genuinely interesting: it's not synthesized in the nucleus like most proteins. It's encoded in mitochondrial DNA, the ancient genome your cells carry from a billion years of evolution.

Think of it like a distress signal that your mitochondria send out when they're under metabolic stress. When energy demand spikes, when glucose is scarce, when you're exercising hard, MOTS-C gets released into the bloodstream and travels to tissues that need to recalibrate their energy use. It activates AMPK (your cells' low-fuel warning light and metabolic master switch), improves insulin sensitivity in muscle tissue, and appears to help cells shift toward fatty acid oxidation — essentially getting better at burning fat for fuel.

Naturally circulating MOTS-C levels decline with age. In one study, circulating MOTS-C was significantly lower in older adults compared to younger ones, and lower still in people with insulin resistance. That's the rationale for exogenous dosing: repleting something your mitochondria are producing less of.

How MOTS-C Works: The Mechanism (Without the Textbook)

Ready for some biology that won't put you to sleep? The short version is this: MOTS-C acts like a metabolic translator between your mitochondria and the rest of your body.

When MOTS-C reaches skeletal muscle, it activates the AMPK pathway (think of AMPK as a fuel gauge that, when it dips low, forces your cells to become more efficient). This triggers glucose uptake independent of insulin — which is a big deal for anyone with insulin resistance or metabolic dysfunction. It also promotes the folate cycle and one-carbon metabolism, which are fancy ways of saying it helps your cells handle the biochemical consequences of energetic stress more cleanly.

More recently, researchers have shown that MOTS-C can enter the nucleus and directly regulate gene expression — essentially acting like a hormone as well as a signaling peptide. That dual role is part of why its effects are so broad: it touches metabolism, inflammation, muscle function, and potentially even aging at the cellular level.

Here's the catch, though. Almost all of the mechanistic data comes from mouse studies and cell cultures. The human trials are small, early, and largely focused on exercise performance and insulin sensitivity. We're extrapolating more than we're confirming. Keep that in mind as you read the dosing section.

MOTS-C Peptide Dosage Chart: By Goal

There is no FDA-approved dose for MOTS-C because it's not FDA-approved for any indication. What exists are extrapolations from research doses used in studies, adjusted for human body weight, and protocols developed by compounding pharmacies and clinical practices working in the longevity space. These ranges are not arbitrary — but they're also not settled science. A clinician should be involved in any protocol you start.

General Starting Range

Most clinical protocols for MOTS-C use a subcutaneous injection dose of 5 mg to 10 mg per injection, administered 2-5 times per week. That's a wide range because it genuinely depends on the goal, the person, and tolerance over the first few weeks.

Dosage by Goal

• Metabolic health and insulin sensitivity: 5 mg, 3x per week is the most commonly used starting point in this context. The goal is steady activation of AMPK pathways without overshooting. Some protocols run at 5 mg daily for a shorter cycle (4-6 weeks) and then reduce frequency.
• Weight loss and body composition: 5-10 mg, 3-5x per week. The evidence here leans on MOTS-C's ability to shift substrate utilization toward fat oxidation and improve mitochondrial efficiency. Higher frequency dosing (5x/week) is sometimes used for the first 4-6 weeks, then tapered. Pairing with fasted-state exercise appears to be the most logical protocol based on mechanism, though direct human trial data is limited.
• Exercise performance and recovery: 10 mg, 3-5x per week, ideally timed 30-60 minutes before training. One of the few human studies — a small trial in older adults — showed that exogenous MOTS-C improved physical performance measures, lending some credibility to the pre-workout timing approach. This is also the dose range most commonly used in active populations in clinical practice.
• Longevity and general cellular health: 5 mg, 2-3x per week. Here the rationale is more about repleting age-related decline in endogenous levels than driving an acute performance effect. Lower frequency, longer cycles, more emphasis on biomarker monitoring.

MOTS-C Dosage Summary Table

Injection Timing: Does It Matter?

Short answer: probably yes, but we don't have tight human data to be definitive about it. Here's the reasoning based on mechanism.

Because MOTS-C is released naturally during exercise and fasting states, it makes conceptual sense to dose it before conditions that mimic those states. Pre-workout administration (30-60 minutes before training) is the most common timing recommendation in performance-focused protocols, and the one with the most logical backing. Some clinicians recommend morning dosing on non-training days to align with the body's natural metabolic rhythms. Evening dosing has no clear rationale and is generally avoided.

Subcutaneous injection into the abdomen or thigh is the standard delivery route. Intramuscular injection is sometimes used for performance protocols, but subcutaneous is simpler and appears sufficient for systemic effect.

Cycling MOTS-C: When to Stop (And Start Again)

Continuous, indefinite dosing isn't how peptide protocols typically work, and MOTS-C is no exception. The most common cycling structure is 8-12 weeks on, 4-8 weeks off. The rationale is partly about avoiding receptor desensitization and partly about the fact that we just don't have long-term safety data justifying year-round use.

For longevity-focused protocols, some clinicians run MOTS-C in 12-week cycles, 2-3 times per year, using biomarker assessments (fasting insulin, HOMA-IR, HbA1c, lipid panels) to track whether the intervention is actually moving the needle. If you're using it for exercise performance, shorter cycles (6-8 weeks) aligned with training blocks are a reasonable approach.

The plot twist: stopping cold is fine. MOTS-C doesn't create physiological dependence. But you should expect that any metabolic improvements are partially sustained by lifestyle factors — diet, exercise, sleep — and won't just persist on their own once you come off the peptide.

MOTS-C Dosing for Women: A Meaningful Difference

This is where the dosing conversation gets more nuanced, and where a lot of generic dosage guides fall short. Women aren't just smaller men with different hormones — the interaction between MOTS-C and female endocrine biology is something researchers are actively studying.

A notable 2023 paper in Nature Aging found that MOTS-C has sexually dimorphic effects: it significantly improved physical performance in older male mice but the effects were more modest in females, particularly in the context of estrogen levels. This doesn't mean MOTS-C doesn't work for women — it likely does — but it does suggest that the dose-response curve may differ.

In clinical practice, lower starting doses for women are common: 5 mg, 2-3x per week as a baseline regardless of goal, with upward adjustment based on response rather than defaulting to the higher male-pattern dosing. Women in perimenopause or postmenopause may respond differently than premenopausal women, given the interplay between estrogen signaling and mitochondrial function.

If you're a woman considering MOTS-C, this is precisely the situation where personalized clinical oversight matters. A protocol built around your hormonal status, metabolic markers, and training context will outperform a cookie-cutter dose every time.

What the Evidence Actually Shows (And What It Doesn't)

Let's be real about what we're working with here.

The strongest evidence for MOTS-C comes from animal models. In mice, it's fairly impressive: reduced obesity, improved insulin sensitivity, extended lifespan in some contexts. In humans, the data is much thinner. Here's what we actually have:

• A 2021 randomized controlled trial in older adults (published in Nature Aging) showed that a single injection of MOTS-C improved physical performance metrics, including grip strength and a walking speed test. Small sample. Real effect. Worth noting.
• Observational studies show that naturally circulating MOTS-C levels correlate inversely with insulin resistance and obesity — meaning people with better metabolic health tend to have more of it. This is associational, not causal.
• Mechanistic data in human cells strongly supports the AMPK activation story. That part is well-established. Whether exogenous dosing over weeks produces meaningful clinical outcomes in healthy or metabolically impaired humans is less clear.

You are not a mouse. The longevity effects seen in rodent studies may not translate cleanly. The metabolic and performance effects are more plausible in humans based on the limited trial data we have. Don't let anyone sell you MOTS-C as a proven anti-aging drug. It's a promising, biologically compelling peptide with early human data. That's a meaningful but honest statement.

Who Is MOTS-C Actually Right For?

MOTS-C is likely most relevant for you if you fall into one or more of these categories:

• You're 40 or older and experiencing declining energy, metabolic slowdown, or reduced training response — conditions that align with age-related MOTS-C decline.
• You have insulin resistance or prediabetes and are looking for adjunctive support beyond lifestyle changes. MOTS-C's insulin-sensitizing mechanism is its most evidence-supported effect in humans.
• You're a serious athlete or highly active person looking to optimize mitochondrial efficiency and recovery, particularly for endurance or strength training.
• You're building a longevity stack and want a mitochondria-targeted intervention alongside other metabolic interventions.
• You're not looking for a shortcut. MOTS-C works best when diet, exercise, and sleep are already dialed in. It's a lever, not a replacement.

It's probably not right for you if you're under 35 with no metabolic issues and excellent baseline metabolic health — endogenous MOTS-C levels are likely adequate. And it's not right for you if you're going to skip the labs and clinical supervision, because dosing without baseline and follow-up biomarkers is just guessing.

Risks and Side Effects: What to Know

MOTS-C has a relatively clean safety profile in the limited human data available. That said, "limited data" is itself the main caveat. Here's what's known:

• Injection site reactions: Redness, minor swelling, or bruising at the subcutaneous injection site. Common with any peptide injection, typically mild and transient.
• Hypoglycemia risk: Because MOTS-C improves insulin sensitivity and glucose uptake, there's a theoretical risk of blood sugar dropping too low, particularly if you're also on insulin, metformin, or other glucose-lowering agents. Monitoring is important.
• Unknown long-term effects: There are no long-term human safety studies. This is the honest reality. Clinical protocols use cycles partly for this reason.
• Purity and sourcing risk: MOTS-C purchased from unregulated peptide vendors carries real contamination risk. Compounded peptides from licensed pharmacies under physician oversight are an entirely different category than "research peptide" suppliers.
• Drug interactions: Particularly relevant if you're on glucose-lowering drugs. A clinician needs to know your full medication list before starting.

Clinical supervision isn't a formality here. It's the thing that turns a peptide protocol from a risk into a reasonable intervention.

How to Get Started With MOTS-C Through Healthspan

Healthspan approaches MOTS-C as part of a broader metabolic and mitochondrial health strategy, not as a standalone injection you self-administer based on a forum post. The right entry point depends on what you're actually trying to optimize.

If your primary goal is metabolic health, insulin sensitivity, or body composition, the AMPK Blend is a clinically designed protocol that targets the same AMPK pathway MOTS-C activates, combining compounds with more established human evidence profiles. It's a strong starting point for anyone building a metabolic longevity foundation.

For a broader mitochondrial approach — covering mitophagy, mitochondrial biogenesis, and cellular energy — the Mitophagy Formula complements peptide-based interventions by addressing the health of the mitochondria themselves, not just their signaling output.

If you're coming at this from an exercise performance and body composition angle and want structured GLP-1 or metabolic support alongside peptide therapy, the CGM Metabolic Protocol gives you real-time glucose data to understand how your metabolism is actually responding — which is exactly the kind of objective feedback that makes peptide dosing decisions rational rather than speculative.

Every Healthspan protocol begins with a physician consultation and baseline labs, so dosing decisions are grounded in your actual biomarkers, not population averages. Monitoring is built in. Adjustments happen based on data. That's what separates a clinical protocol from a guess.

If you're ready to stop piecing together a protocol from forum posts and start one built around your labs and your goals, book a consultation with Healthspan and find out which mitochondrial health approach makes sense for you.

Frequently Asked Questions About MOTS-C Dosage

What is the standard MOTS-C peptide dosage for beginners?

Most clinical protocols start at 5 mg per injection, 3 times per week, administered subcutaneously. This is considered a conservative starting dose that allows you to assess tolerance and response before adjusting. Higher doses (up to 10 mg) are used for performance-focused protocols, but starting low and titrating based on response is the safer approach, especially without prior peptide experience.

How often should you inject MOTS-C?

Injection frequency depends on your goal. Metabolic health protocols typically run 3 injections per week. Performance and body composition protocols may use 3-5 injections per week. There's no strong human evidence that daily dosing outperforms every-other-day dosing — more frequent isn't automatically better with peptides, and cycling is generally recommended over indefinite daily use.

How long does a MOTS-C cycle last?

Most protocols run 6-12 weeks on, followed by 4-8 weeks off. Shorter cycles (6-8 weeks) are common for performance-focused use. Longer cycles (10-12 weeks) are used for metabolic health and longevity goals. The off period allows assessment of sustained effects and is a precaution given the lack of long-term human safety data.

Does MOTS-C dosage differ for women?

Yes, meaningfully so. Research suggests MOTS-C's effects may be sexually dimorphic, with potentially different dose-response relationships for women, particularly around estrogen status. Women typically start at the lower end of the dosing range (5 mg, 2-3x per week) and adjust based on response. Women in perimenopause or postmenopause should have their hormonal context factored into any peptide protocol.

When should you inject MOTS-C for best results?

Pre-workout timing (30-60 minutes before exercise) is the most commonly used approach for performance protocols, based on the peptide's mechanism of action during energetic stress. Morning dosing on non-training days is a reasonable alternative. There's no strong human trial data comparing timing protocols directly, but mechanistic reasoning supports pre-exercise administration for metabolic and performance goals.

Can you stack MOTS-C with other metabolic peptides or drugs?

MOTS-C is sometimes used alongside other metabolic interventions, but stacking requires careful clinical oversight. Combining with insulin-sensitizing agents (like metformin or SGLT2 inhibitors) may amplify glucose-lowering effects and increase hypoglycemia risk. Stacking with other mitochondria-targeted peptides (like Humanin) is being studied but lacks robust human data. Always disclose your full protocol to a prescribing clinician before adding MOTS-C.

Is MOTS-C safe to use long-term?

The honest answer is we don't know. Long-term human safety data simply doesn't exist yet. The short-term profile looks relatively clean in the limited trials available, but that's not the same as a long-term safety record. This is why cycling protocols (rather than continuous use) and regular biomarker monitoring are strongly recommended. Clinical supervision is not optional — it's the framework that makes long-term use responsible rather than reckless.